Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Actinic Keratosis Pipeline Drugs Market Overview

An actinic keratosis, also known as solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck, or any other areas of the body frequently exposed to the sun. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, blue or light-colored eyes, and a weak immune system because of chemotherapy, chronic leukemia, AIDS, or organ transplant medications.

The Actinic Keratosis pipeline market research report provides comprehensive information on the therapeutics under development for Actinic Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic Keratosis and features dormant and discontinued projects.

Key Targets Tubulin, Tyrosine Protein Kinase CSK, Cannabinoid Receptor 2, Tumor Necrosis Factor Receptor Superfamily Member 1A, Tumor Necrosis Factor Receptor Superfamily Member 6, Cannabinoid Receptor 1, Caspase 9, Cytosolic Phospholipase A2, DNA, Epidermal Growth Factor Receptor, and Others
Key Mechanisms of Action Tubulin Inhibitor, Tyrosine Protein Kinase CSK Inhibitor, Cannabinoid Receptor 2 Agonist, Tumor Necrosis Factor Receptor Superfamily Member 1A Agonist, Tumor Necrosis Factor Receptor Superfamily Member 6 Agonist, Cannabinoid Receptor 1 Agonist, Caspase 9 Activator, Cytosolic Phospholipase A2 Inhibitor, DNA Synthesis Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and Others
Key Routes of Administration Topical, Oral, Cutaneous, Inhalational, Intravenous, Parenteral, Transdermal, Intraperitoneal, Intratumor, Intravesical, and Others
Key Molecule Type Small Molecule, Enzyme, Gene Therapy, and Monoclonal Antibody
Major Companies Athenex Inc, G&E Herbal Biotechnology Co., Ltd, Claradele Pharmaceuticals Inc, Coegin Pharma AS, Ingenew Pharmaceuticals Inc, Invion Ltd, Jupiter Wellness Inc, Laboratories Ojer Pharma SL, MedC Biopharma Ltd, and MediWound Ltd

 

Key Targets in the Actinic Keratosis Pipeline Products Market

The key targets in the Actinic Keratosis pipeline products market are Tubulin, Tyrosine Protein Kinase CSK, Cannabinoid Receptor 2, Tumor Necrosis Factor Receptor Superfamily Member 1A, Tumor Necrosis Factor Receptor Superfamily Member 6, Cannabinoid Receptor 1, Caspase 9, Cytosolic Phospholipase A2, DNA, Epidermal Growth Factor Receptor, and others.

Actinic Keratosis Pipeline Products Analysis Market by Targets, 2022 (%)

Actinic Keratosis Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Actinic Keratosis Pipeline Products Market

The key mechanisms of action in the Actinic Keratosis pipeline products market are Tubulin Inhibitor, Tyrosine Protein Kinase CSK Inhibitor, Cannabinoid Receptor 2 Agonist, Tumor Necrosis Factor Receptor Superfamily Member 1A Agonist, Tumor Necrosis Factor Receptor Superfamily Member 6 Agonist, Cannabinoid Receptor 1 Agonist, Caspase 9 Activator, Cytosolic Phospholipase A2 Inhibitor, DNA Synthesis Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and others.

Actinic Keratosis Pipeline Products Market Analysis by Mechanisms of Action, 2022 (%)

Actinic Keratosis Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Actinic Keratosis Pipeline Products Market

The key routes of administration in the Actinic Keratosis pipeline products market are topical, oral, cutaneous, inhalational, intravenous, parenteral, transdermal, intraperitoneal, intratumor, intravesical, and others.

Actinic Keratosis Pipeline Products Market Analysis by Routes of Administration, 2022 (%)

Actinic Keratosis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Actinic Keratosis Pipeline Products Market

The key molecule types in the Actinic Keratosis pipeline products market are small molecule, enzyme, gene therapy, and monoclonal antibody.

Actinic Keratosis Pipeline Products Market Analysis by Molecule Types, 2022 (%)

Actinic Keratosis Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights, download a free report sample

Major Companies in the Actinic Keratosis Pipeline Products Market

Some of the major companies in the Actinic Keratosis pipeline products market are Athenex Inc, G&E Herbal Biotechnology Co., Ltd, Claradele Pharmaceuticals Inc, Coegin Pharma AS, Ingenew Pharmaceuticals Inc, Invion Ltd, Jupiter Wellness Inc, Laboratories Ojer Pharma SL, MedC Biopharma Ltd, and MediWound Ltd.

Athenex Inc: Athenex Inc (Athenex), formerly known as Kinex Pharmaceuticals Inc, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of paclitaxel (Oraxol), irinotecan (Oratecan), and docetaxel (Oradoxel) for the treatment of metastatic breast, colorectal, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancers. Its Src kinase product candidates comprises KX-01, a novel orally administered small molecule compound for the treatment of actinic keratosis; and KX-02 for solid tumors.

Actinic Keratosis Pipeline Products Market Analysis by Companies, 2022 (%)

Actinic Keratosis Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Athenex Inc
Claradele Pharmaceuticals Inc
Coegin Pharma AS
G&E Herbal Biotechnology Co., Ltd.
Ingenew Pharmaceuticals Inc
Invion Ltd
Jupiter Wellness Inc
Laboratories Ojer Pharma SL
MedC Biopharma Ltd
MediWound Ltd
Nanology LLC
Neonc Technologies Inc
Oncology Research International Ltd
Ponce Therapeutics Inc
Provectus Biopharmaceuticals Inc
RepoCeuticals ApS
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Singh Biotechnology LLC
Sol-Gel Technologies Ltd
Vidac Pharma

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Actinic (Solar) Keratosis – Overview

Actinic (Solar) Keratosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Actinic (Solar) Keratosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Actinic (Solar) Keratosis – Companies Involved in Therapeutics Development

Actinic (Solar) Keratosis – Drug Profiles

Actinic (Solar) Keratosis – Dormant Projects

Actinic (Solar) Keratosis – Discontinued Products

Actinic (Solar) Keratosis – Product Development Milestones

Featured News & Press Releases

Feb 18, 2022: Jupiter Wellness completes enrollment in double-blind placebo-controlled clinical trial of JW-200 for the treatment of actinic keratosis

Oct 14, 2021: Indicative announcement aminolevulinic acid hydrochloride topical powder received the acceptance notice for the investigational new drug application

Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe

Sep 20, 2021: Vidac Pharma announces wider spectrum authorization of its CTCL phase 2 clinical trial

Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis

May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis

Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis

Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additional territories for tirbanibulin

Feb 11, 2021: Athenex announces New England Journal of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)

Dec 15, 2020: Almirall announces FDA approval of Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis

Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis

Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis

Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment

Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting

Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Actinic (Solar) Keratosis – Pipeline by Athenex Inc, 2022

Actinic (Solar) Keratosis – Pipeline by Claradele Pharmaceuticals Inc, 2022

Actinic (Solar) Keratosis – Pipeline by Coegin Pharma AS, 2022

Actinic (Solar) Keratosis – Pipeline by G&E Herbal Biotechnology Co., Ltd., 2022

Actinic (Solar) Keratosis – Pipeline by Ingenew Pharmaceuticals Inc, 2022

Actinic (Solar) Keratosis – Pipeline by Invion Ltd, 2022

Actinic (Solar) Keratosis – Pipeline by Jupiter Wellness Inc, 2022

Actinic (Solar) Keratosis – Pipeline by Laboratories Ojer Pharma SL, 2022

Actinic (Solar) Keratosis – Pipeline by MedC Biopharma Ltd, 2022

Actinic (Solar) Keratosis – Pipeline by MediWound Ltd, 2022

Actinic (Solar) Keratosis – Pipeline by Nanology LLC, 2022

Actinic (Solar) Keratosis – Pipeline by Neonc Technologies Inc, 2022

Actinic (Solar) Keratosis – Pipeline by Oncology Research International Ltd, 2022

Actinic (Solar) Keratosis – Pipeline by Ponce Therapeutics Inc, 2022

Actinic (Solar) Keratosis – Pipeline by Provectus Biopharmaceuticals Inc, 2022

Actinic (Solar) Keratosis – Pipeline by RepoCeuticals ApS, 2022

Actinic (Solar) Keratosis – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022

Actinic (Solar) Keratosis – Pipeline by Singh Biotechnology LLC, 2022

Actinic (Solar) Keratosis – Pipeline by Sol-Gel Technologies Ltd, 2022

Actinic (Solar) Keratosis – Pipeline by Vidac Pharma, 2022

Actinic (Solar) Keratosis – Dormant Projects, 2022

Actinic (Solar) Keratosis – Dormant Projects, 2022 (Contd..1)

Actinic (Solar) Keratosis – Dormant Projects, 2022 (Contd..2)

Actinic (Solar) Keratosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.